Added to YB: 2025-12-30
Pitch date: 2025-12-29
HROW [bullish]
Harrow, Inc.
+0.26%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
$1.9B
Pitch Price
$50.69
Price Target
N/A
Dividend
N/A
EV/EBITDA
42.87
P/E
-368.75
EV/Sales
8.18
Sector
Pharmaceuticals
Category
growth
The portfolio I am taking into 2026 - Harrow, Inc.
HROW: Ophthalmology co leveraging unique distribution to scale neglected eye drugs from Big Pharma at low prices. Growth drivers: Vevye (dry eye) market share gains, biosimilars scaling, MELT-300 sedative (2028+ beyond ophthalmology). Target $250M Q4/27 rev at 30-40% op margin. 2027: 20x PE, 10x EV/EBITDA for 30%+ growth thru 2029.
Read full article (1 min)